AbCellera to present Phase 1/2 ABCL635 data

AbCellera said it will present Phase 1/2 data on ABCL635 at The Menopause Society's 2026 Annual Meeting in San Diego later this month. The poster will include new safety and patient-reported outcome data from the company's Phase 1 and Phase 2 studies.